Triflusal
SIAL/T2005000 - European Pharmacopoeia (EP) Reference Standard
Synonym: α,α,α-trifluoro-2,4-cresotic acid acetate; 2-
CAS Number: 322-79-2
Empirical Formula (Hill Notation): C10H7F3O4
Molecular Weight: 248.16
Linear Formula: C10H7F3O4
Product Type: Chemical
application(s) | pharmaceutical (small molecule) |
format | neat |
grade | pharmaceutical primary standard |
InChI | 1S/C10H7F3O4/c1-5(14)17-8 |
InChI key | RMWVZGDJPAKBDE-UHFFFAOYSA |
manufacturer/tradename | EDQM |
storage temp. | 2-8°C |
Biochem/physiol Actions: | Triflusal is an anti-inflammatory antithrombotic platelet aggregation inhibitor with a 3-fold mechanism of action. It is an irreversible inhibitor of COX-1 inhibiting thromboxane A2, preventing aggregation; it preserves vascular prostacyclin, thus promoting anti-aggregant effect. Triflusal blocks phosphodiesterase leading to an increase in cAMP levels promoting anti-aggregant effect due to inhibition of calcium mobilization. |
Caution: | Please find SDS provided by EDQM here. . |
General description: | This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia . |
Other Notes: | Sales restrictions may apply. |
Packaging: | Unit quantity: 50 mg. Subject to change. The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue . |
Symbol | GHS07 |
Signal word | Warning |
Hazard statements | H302 - H315 - H317 - H319 - H335 |
Precautionary statements | P261 - P264 - P280 - P280 - P304 + P340 + P312 - P333 + P313 |
RIDADR | NONH for all modes of transport |
WGK Germany | WGK 3 |
Flash Point(F) | Not applicable |
Flash Point(C) | Not applicable |
Storage Temp. | 2-8°C |
UNSPSC | 41116107 |